Performance of CT in the locoregional staging of colon cancer: detailed radiology-pathology correlation with special emphasis on tumor deposits, extramural venous invasion and T staging-Reference-Cited by-同舟云学术

Performance of CT in the locoregional staging of colon cancer: detailed radiology-pathology correlation with special emphasis on tumor deposits, extramural venous invasion and T staging

Published:2024-03-06 Issue:6 Volume:49 Page:1792-1804
ISSN:2366-0058
Container-title:Abdominal Radiology
language:en
Short-container-title:Abdom Radiol

Author:

Karahacioglu Duygu^ORCID,Taskin Orhun Cig^ORCID,Esmer Rohat^ORCID,Armutlu Ayse^ORCID,Saka Burcu^ORCID,Ozata Ibrahim Halil^ORCID,Rencuzogullari Ahmet^ORCID,Bugra Dursun^ORCID,Balik Emre^ORCID,Adsay Volkan^ORCID,Gurses Bengi^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00261-024-04203-0.pdf

Reference41 articles.

1. Fernandes MC, Gollub MJ, Brown G (2022) The importance of MRI for rectal cancer evaluation. Surg Oncol. 43:101739. http://doi:https://doi.org/10.1016/j.suronc.2022.101739

2. Karoui M, Rullier A, Luciani A, Bonnetain F, Auriault M L, Sarran A, Monges G, Trillaud H, Le Malicot K, Leroy K, Sobhani I, Bardier A, Moreau M, Brindel Seitz J F, Taieb J (2015) Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial--the PRODIGE 22--ECKINOXE trial. BMC Cancer 15: 511.

3. Morton D, Seymour M, Magill L, et al (2023) Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial. J Clin Oncol 41(8):1541-1552. http://doi:https://doi.org/10.1200/JCO.22.00046

4. Chalabi M, Fanchi LF, Dijkstra KK, et al (2020) Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med 26(4):566-576. https://doi.org/https://doi.org/10.1038/s41591-020-0805-8

5. Karoui M, Gallois C, Piessen G, et al (2021) Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years' follow-up results of the PRODIGE 22 phase II randomized multicentre trial. Colorectal Dis 23(6):1357-1369. https://doi.org/https://doi.org/10.1111/codi.15585